Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn’s disease patients treated with combined immunosuppressive therapy

Ben Kang\textsuperscript{a,b,c}, So Yoon Choi\textsuperscript{d}, Young Ok Choi\textsuperscript{c}, Min-ji Kim\textsuperscript{e}, Kyunga Kim\textsuperscript{e}, Ji-Hyuk Lee\textsuperscript{f}, Yon Ho Choe\textsuperscript{c}

\textsuperscript{a}Department of Pediatrics, Kyungpook National University School of Medicine, Daegu, Korea

\textsuperscript{b}Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD), Daegu, Korea

\textsuperscript{c}Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

\textsuperscript{d}Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea

\textsuperscript{e}Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea

\textsuperscript{f}Department of Pediatrics, Chungbuk National University College of Medicine, Cheongju, Korea

Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com
Short title: Infliximab cessation in paediatric-onset Crohn's disease

Corresponding author: Yon Ho Choe, MD, PhD, Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. Tel: 82-2-3410-3527, Fax: 82-2-3410-0043, Email: i101016@skku.edu

Conference presentation: Presented at the 12th congress of the European Crohn's and Colitis Organisation (ECCO), 2017, as a digital oral presentation.

List of abbreviations: ADL, adalimumab; ATI, antibody to infliximab; AZA, azathioprine; CD, Crohn's disease; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FC, faecal calprotectin; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel disease; IFX, infliximab; IQR, interquartile range; MH, mucosal healing; MRE, magnetic resonance enterography; PCDAI, Pediatric Crohn's Disease Activity Index; RBC, red blood cell; SES-CD, Simple Endoscopic Score for Crohn's Disease; 6-TGN, 6-thioguanine nucleotides; TL, trough level; TNF, tumour necrosis factor

ABSTRACT

Background and aims: We aimed to investigate the outcome in paediatric-onset Crohn's disease patients who had discontinued infliximab after maintaining clinical remission with combined immunosuppression, and to determine factors associated with clinical relapse.

Methods: We conducted a retrospective observational study of 63 paediatric-onset Crohn's disease patients who had stopped scheduled infliximab during sustained corticosteroid-free clinical remission for at least 1 year with infliximab and azathioprine, and were followed up for at least 1 year thereafter. Cumulative relapse rates and the median time to relapse were estimated statistically. Factors at cessation were also evaluated for their association with clinical relapse.
Results. After a median follow-up period of 4.3 years (range, 1–7.5 years), 60.3% (38/63) of patients had experienced clinical relapse. According to Kaplan–Meier survival analysis, the estimated cumulative relapse rates at 1, 4, and 6 years were 19.0%, 62.2%, and 75.2%, respectively, and the median relapse time was 3.3 years from infliximab cessation. According to multivariate Cox proportional hazard regression analysis, infliximab trough levels of ≥2.5 μg/mL and incomplete mucosal healing were associated with clinical relapse (HR=7.199, 95% CI=1.641–31.571, \( p = 0.009 \) and HR=3.628, 95% CI=1.608–8.185, \( p = 0.002 \), respectively). Although retreatment with infliximab was effective in 90.9% (30/33) of patients, 7.9% (3/38) eventually underwent surgery within 1 year of relapse.

Conclusions. Considering the high cumulative relapse rates in the long term and cases of severe relapse requiring surgery, discontinuing infliximab in paediatric-onset Crohn’s disease patients is currently inadvisable. However, there may be a subgroup of patients who are good candidates for infliximab withdrawal.

KEYWORDS: Infliximab, pharmacokinetics, mucosal healing